|
Daria Donati PhD
Chief Scientific Officer - Genomic Medicines
Cytiva
uppsala
Sweden
|
"Daria Donati is leading the Scientific Office and Innovation for Cytiva Genomic Medicines initaitives.
Daria is also leading the global strategic technology partnerships initiatives, bringing forward-looking technology into the everyday lives of Cytiva customers and employees. To that end, she oversees global collaborations, alliances and technology evaluations.
Daria’s roots are in academia and public health. She has worked with the MIM-TDR (WHO) supporting capacity building in sub-Saharan Africa as International Liaison manager, leading global collaborations and funding management to support sustainable development projects in healthcare.
In the business sector, she has over 20 years of diverse management and technology solution experience within biotech and biomanufacturing. She first joined GE Healthcare in 2008, and has been in her current role in the Chief Science Office since 2022.
She has led key endeavors within vaccine manufacturing solutions and biomanufacturing within Enterprise solutions, which develops and delivers biopharma manufacturing solutions, providing the tools and services to enable speed to market and rapid response, increasing the access to life saving drugs. ology from the University of Pisa, Italy.
Daria was instrumental in driving the development and commercialization of the remarkable KUBio, the first off-the-shelf biomanufacturing facility in the industry, now used by four global customers, enabling production of precision medicines in >13 countries.
Daria is a sought-after speaker at industry and alliance events. In 2017 Daria was named European Businesswoman of the Year 2017 in the category Life Sciences. In 2020 identified as one of the 22 most influential people in fight against COVID-19 by Fierce Pharma.
Her engagement in public health and development of medicines against infectious diseases has brought her to live and work in more than five countries in Africa, Europe and North America. She served as principal investigator working on malaria, infectious diseases, immunology and vaccines at Karolinska Institute in Sweden, from which she earned one PhD in Experimental Medicine. Her second PhD is in Biotechnology and Transplant Immunology from The University of Pisa, Italy, and a Master in Science, with major in Molecular Biology from the University of Pisa, Italy."
Daria is also leading the global strategic technology partnerships initiatives, bringing forward-looking technology into the everyday lives of Cytiva customers and employees. To that end, she oversees global collaborations, alliances and technology evaluations.
Daria’s roots are in academia and public health. She has worked with the MIM-TDR (WHO) supporting capacity building in sub-Saharan Africa as International Liaison manager, leading global collaborations and funding management to support sustainable development projects in healthcare.
In the business sector, she has over 20 years of diverse management and technology solution experience within biotech and biomanufacturing. She first joined GE Healthcare in 2008, and has been in her current role in the Chief Science Office since 2022.
She has led key endeavors within vaccine manufacturing solutions and biomanufacturing within Enterprise solutions, which develops and delivers biopharma manufacturing solutions, providing the tools and services to enable speed to market and rapid response, increasing the access to life saving drugs. ology from the University of Pisa, Italy.
Daria was instrumental in driving the development and commercialization of the remarkable KUBio, the first off-the-shelf biomanufacturing facility in the industry, now used by four global customers, enabling production of precision medicines in >13 countries.
Daria is a sought-after speaker at industry and alliance events. In 2017 Daria was named European Businesswoman of the Year 2017 in the category Life Sciences. In 2020 identified as one of the 22 most influential people in fight against COVID-19 by Fierce Pharma.
Her engagement in public health and development of medicines against infectious diseases has brought her to live and work in more than five countries in Africa, Europe and North America. She served as principal investigator working on malaria, infectious diseases, immunology and vaccines at Karolinska Institute in Sweden, from which she earned one PhD in Experimental Medicine. Her second PhD is in Biotechnology and Transplant Immunology from The University of Pisa, Italy, and a Master in Science, with major in Molecular Biology from the University of Pisa, Italy."